Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide-dexamethasone Alone or in Combination With Daratumumab in Transplant Ineligible Newly Diagnosed Multiple Myeloma
NCT05527340Phase 2Active, not recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Dec 2022
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iberdomide in multiple myeloma (MM), sponsored by Fundación PETHEMA. Started Dec 2022; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05527340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527340.